JP2022549222A5 - - Google Patents

Info

Publication number
JP2022549222A5
JP2022549222A5 JP2022517875A JP2022517875A JP2022549222A5 JP 2022549222 A5 JP2022549222 A5 JP 2022549222A5 JP 2022517875 A JP2022517875 A JP 2022517875A JP 2022517875 A JP2022517875 A JP 2022517875A JP 2022549222 A5 JP2022549222 A5 JP 2022549222A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dioxopiperidine
carboxamide
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051997 external-priority patent/WO2021061642A1/en
Publication of JP2022549222A publication Critical patent/JP2022549222A/ja
Publication of JP2022549222A5 publication Critical patent/JP2022549222A5/ja
Pending legal-status Critical Current

Links

JP2022517875A 2019-09-23 2020-09-22 アンドロゲン受容体分解活性を有する新規尿素およびその使用 Pending JP2022549222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903997P 2019-09-23 2019-09-23
US62/903,997 2019-09-23
PCT/US2020/051997 WO2021061642A1 (en) 2019-09-23 2020-09-22 Novel ureas having androgen receptor degradation activity and uses thereof

Publications (2)

Publication Number Publication Date
JP2022549222A JP2022549222A (ja) 2022-11-24
JP2022549222A5 true JP2022549222A5 (cg-RX-API-DMAC7.html) 2023-09-28

Family

ID=74879893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517875A Pending JP2022549222A (ja) 2019-09-23 2020-09-22 アンドロゲン受容体分解活性を有する新規尿素およびその使用

Country Status (5)

Country Link
US (3) US11420956B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034114A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022549222A (cg-RX-API-DMAC7.html)
CN (1) CN114761003B (cg-RX-API-DMAC7.html)
WO (1) WO2021061642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
WO2020160295A1 (en) 2019-01-30 2020-08-06 Montelino Therapeutics, Llc Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. Novel ureas having androgen receptor degradation activity and uses thereof
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
WO2022019597A1 (ko) * 2020-07-21 2022-01-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
US20240376118A1 (en) * 2021-09-13 2024-11-14 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
KR20230112501A (ko) 2022-01-20 2023-07-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해활성을 갖는 화합물 및 이들의 의약 용도
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications
US20240190842A1 (en) * 2022-11-09 2024-06-13 Accutar Biotechnology Inc. Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740140D1 (de) * 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
WO2000017163A1 (en) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
ES2393333T3 (es) * 2002-07-12 2012-12-20 Astellas Pharma Inc. Derivado de N-fenil-(2R,5S)dimetilpiperazina
WO2005011011A1 (en) * 2003-07-21 2005-02-03 Unaxis Usa Inc. Etching method for making chalcogenide memory elements
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20130197009A1 (en) * 2010-10-22 2013-08-01 Astellas Pharma Inc. Antagonist for mutant androgen receptor
BR122017017921A2 (pt) * 2012-07-27 2019-09-10 Aragon Pharmaceuticals, Inc. métodos e sistema para determinar a resistência à terapia de receptor de androgênio
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
SI3526202T1 (sl) * 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
IL325835A (en) * 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. Novel ureas having androgen receptor degradation activity and uses thereof

Similar Documents

Publication Publication Date Title
IL291590B2 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
US12083118B2 (en) Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
KR102271574B1 (ko) 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
JP2020503297A5 (cg-RX-API-DMAC7.html)
JP2022185107A5 (cg-RX-API-DMAC7.html)
RU2704129C2 (ru) Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2023536164A5 (cg-RX-API-DMAC7.html)
JP2016513660A5 (cg-RX-API-DMAC7.html)
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
US20210261542A1 (en) Compounds which inhibit rna polymerase, compositions including such compounds, and their use
JP2016525078A5 (cg-RX-API-DMAC7.html)
JP2008528467A5 (cg-RX-API-DMAC7.html)
JP2015517574A5 (cg-RX-API-DMAC7.html)
JP2016522246A5 (cg-RX-API-DMAC7.html)
RU2009144191A (ru) Имидазопиридиновые ингибиторы киназ
JP6896701B2 (ja) イミダゾリルアミド誘導体
JP2007504160A5 (cg-RX-API-DMAC7.html)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2014520108A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
HRP20220472T1 (hr) Novi derivati heteroarilamida kao selektivni inhibitori histonskih deacetilaza 1 i 2 (hdac1-2)
JP2009537542A5 (cg-RX-API-DMAC7.html)